Pharmaceutical composition for stroke treatment based on ampk inhibition

9:

• The method of claim 8, wherein the stroke includes hemorrhagic stroke, ischemic stroke or metal toxicity stroke.

10:

• The method of claim 8, wherein the stroke is caused by toxicity of metal selected from the group consisting of lead, mercury, manganese, arsenic, thallium, iron, zinc, cadmium, bismuth, tin, and a combination thereof.

11:

• The method of claim 9, wherein the stroke includes the ischemic stroke derived from excitotoxic neuronal death or oxidative neuronal death.

12:

• The method of claim 8, wherein R1 to R5 each is independently a trifluoromethyl group.

13:

• The method of claim 8, wherein R1 to R5 are each independently iodine, bromine or chlorine.

14:

• The method of claim 8, wherein the compound is (5Z)-5-(1H-Indol-3-ylmethylene)-2-{[2-(trifluoromethyl)phenyl]amino}-1,3-thiazol-4(5H)-one, (5Z)-5-(1H-Indol-3-ylmethylene)-2-{[3-(trifluoromethyl)phenyl]amino}-1,3-thiazol-4(5H)-one, (5Z)-2-[(3-Bromophenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one, (5Z)-5-(1H-Indol-3-ylmethylene)-2-[(4-methylphenyl)amino]-1,3-thiazol-4(5H)-one, (5Z)-5-(1H-Indol-3-ylmethylene)-2-[(3-methylphenyl)amino]-1,3-thiazol-4(5H)-one, (5Z)-2-Anilino-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one, no]-1,3-thiazol-4(5H)-one, (5E)-5-[(2-Methyl-1H-indol-3-yl)methylene]-2-[(4-methylphenyl)amino]-1,3-thiazol-4(5H)-one, 3-{[(5Z)-5-(1H-Indol-3-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]amino}benzoic acid, 2-{[(5E)-5-(1H-Indol-3-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]amino}benzoic acid, (5Z)-2-[(2-Chlorophenyl)amino]-5-[(2-methyl-1H-indol-3-yl)methylene]-1,3-thiazol-4(5H)-one, or 2-Hydroxy-5-{[(5Z)-5-(1H-indol-3-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]amino}benzoic acid.

15:

• The method of claim 8, wherein R2 and R3 together form a —O—(CH2)n—O— ring or a substituted or unsubstituted benzene ring.